Bernd Muehlenweg

Bernd Muehlenweg's work experience includes various senior leadership roles in the biotech and pharmaceutical industry. Bernd currently serves as the Senior Vice President of Global Business Development at Evotec, where they lead the company's efforts in areas such as cell therapy, precision medicine, oncology, immunology, and infectious diseases. Bernd is also responsible for overseeing the business development and licensing activities of Evotec's Innovate segment. Prior to joining Evotec, Muehlenweg co-founded Panoptes Pharma GmbH, a biotech company focused on developing therapies for eye diseases, which was later acquired by Eyegate Pharmaceuticals. Bernd also held the position of Chief Business Officer and served on the Executive Board of Nanobiotix, a pre-clinical biotech company. Additionally, they have experience in business development and alliance management at Wilex AG, where they played a key role in the company's growth and expansion. Muehlenweg began their career as a Group Leader at the Technical University Munich.

Bernd Muehlenweg attended the St. Galler Business School in 2006, where they studied Management. Prior to that, they pursued a Ph.D. in Oncology and Biochemistry at the Technical University of Munich from 1997 to 2000. Bernd obtained their Dipl. Chem. degree in Chemistry and Biochemistry from Bielefeld University between 1991 and 1996. In 1995, Bernd Muehlenweg also briefly studied Biophysical Chemistry at Dublin City University.